Drug Trial Radar · NCT07595874
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 16, 2028
Study completion Dec 16, 2028
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.
Conditions
- Advanced Colon Adenocarcinoma
- Advanced Colorectal Adenocarcinoma
- Advanced Rectal Adenocarcinoma
- Stage IIB Colon Cancer AJCC v8
- Stage IIB Rectal Cancer AJCC v8
- Stage IIC Colon Cancer AJCC v8
- Stage IIC Rectal Cancer AJCC v8
- Stage IIIA Colon Cancer AJCC v8
- Stage IIIA Rectal Cancer AJCC v8
- Stage IIIB Colon Cancer AJCC v8
- Stage IIIB Rectal Cancer AJCC v8
- Stage IIIC Colon Cancer AJCC v8
- Stage IIIC Rectal Cancer AJCC v8
Interventions
BalstilimabBiological
Given IV
Biospecimen CollectionProcedure
Undergo blood sample collection
BotensilimabBiological
Given IV
Computed TomographyProcedure
Undergo CT scan
Magnetic Resonance ImagingProcedure
Undergo MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Two-year disease-free survival rateTime frame: At 2 years post enrollment
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
CTCA at Western Regional Medical Center
Goodyear, Arizona · Recruiting
City of Hope Corona
Corona, California · Recruiting
City of Hope Medical Center
Duarte, California · Recruiting
City of Hope Seacliff
Huntington Beach, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
City of Hope South Pasadena
South Pasadena, California · Recruiting
City of Hope Upland
Upland, California · Recruiting
City of Hope Atlanta Cancer Center
Newnan, Georgia · Recruiting
City of Hope at Illinois Chicago Downtown
Chicago, Illinois · Recruiting
City of Hope at Chicago
Zion, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.